Sign Up to Receive Your Personalised Learning Resources
JOURNALS
SARS-CoV-2 mRNA vaccination associated with increased survival in patients with lung cancer and melanoma treated with immune checkpoint inhibitors
Start Learning
The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
ESGO 24: Advances in cervical, endometrial and ovarian cancer
Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements
Precision targeting of MET in NSCLC: A multidisciplinary approach
Key data in gastrointestinal cancer: ESOPEC, TRANSMET, COLLISION, ARC-9
Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer
Nivolumab plus Relatlimab alongside chemotherapy demonstrated improved clinical benefit in the RELATIVITY-104 trial
Breast cancer highlights: DESTINY-Breast06, postMONARCH, TBCRC 048
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
Trastuzumab Deruxtecan for the Treatment of HER2-low Advanced or Metastatic Breast Cancer
View
Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer
View
Is prostate cancer overdiagnosis a risk in Europe’s screening efforts?
View
A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy
View
Trending at #ASCO2024
View
Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma
View
Nivolumab plus Relatlimab alongside chemotherapy demonstrated improved clinical benefit in the RELATIVITY-104 trial
View
Trastuzumab deruxtecan shows clinical benefit in patients with HER2-ultralow metastatic breast cancer
View
Transarterial chemoembolization with lenvatinib and pembrolizumab showed improvement in progression-free survival for hepatocellular carcinoma
View
Personalizing care within the MDT for patients with early through to advanced RCC
View
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
